ArticleFrontiers in oncology2021
Real-Time
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Preoperative contrast-enhanced ultrasound combined with intra-lymph node methylene blue injection for sentinel lymph node identification: a minimally invasive sentinel lymph node biopsy tracing approach.European radiology · 2026Trial
- Navigating lymphatic drainage uncertainty in abdominal ectopic breast cancer: a novel application of indocyanine green fluorescence-a case report and literature review.International cancer conference journal · 2026Article
- Lymphatic topology reveals a novel intranodal lympho-venous shunt.The Journal of pathology · 2026Article
- A Novel Fluorescence-Triggered Auditory Feedback Photosensor for Precision Lymph Node Mapping.Sensors (Basel, Switzerland) · 2026Article
- Clinicopathological factors associated with sentinel lymph node positivity in breast cancer using indocyanine green: a retrospective study in Peru.World journal of surgical oncology · 2026Article
- Comparative analysis of indocyanine green and technetium-99m for sentinel lymph node localization in breast cancer - institutional experience.Frontiers in oncology · 2026Article
- Fluorescence lymph node mapping using ICG improves lateral lymph node dissection for mid-low rectal cancer: a propensity score-matched cohort.Techniques in coloproctology · 2025Article
- An Updated Review on the Emerging Role of Indocyanine Green (ICG) as a Sentinel Lymph Node Tracer in Breast Cancer.Cancers · 2023Review
- Single Quasi-Symmetrical LED with High Intensity and Wide Beam Width Using Diamond-Shaped Mirror Refraction Method for Surgical Fluorescence Microscope Applications.Diagnostics (Basel, Switzerland) · 2023Article
- Indocyanine Green Fluorescence Imaging in the Surgical Management of Skin Squamous Cell Carcinoma.Clinical, cosmetic and investigational dermatology · 2023Article
- NIR-II and visible fluorescence hybrid imaging-guided surgery via aggregation-induced emission fluorophores cocktails.Materials today. Bio · 2022Article
- Bioactive cationic peptides as potential agents for breast cancer treatment.Bioscience reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe naked-eye invisibility of indocyanine green fluorescence limits the application of near-infrared fluorescence imaging (NIR) systems for real-time navigation during sentinel lymph node biopsy (SLNB) in patients with breast cancer undergoing surgery. This study aims to evaluate the effectiveness and safety of a novel NIR system in visualizing indocyanine green fluorescence images in the surgical field and the application value of combined methylene blue (MB) and the novel NIR system in SLNB.
methodsSixty patients with clinical node-negative breast cancer received indocyanine green (ICG) and MB as tracers. Two NIR system instruments, namely, lymphatic fluorescence imaging system (LFIS) designed by the University of Science and Technology of China and vascular imager by Langfang Mingde Medical Biotechnology Co., Ltd. (Langfang vascular imager), were used as navigation assistance to locate sentinel lymph nodes (SLNs). Excising the lymph nodes developed by both MB and ICG by two NIR systems or palpably suspicious as SLNs and undergoing rapid pathological examination.
resultsBoth instruments exhibited 95% (57/60) success for real-time lymphatic fluorescent images. A total of 186 SLNs were identified, of which two were pathologically confirmed as lacking any lymph node tissue. SLN identification rate was 100% (184/184) for MB plus LFIS and 86.96% (160/184) for MB alone. The median number of SLNs identified by LFIS combined with MB was 3 (range of 1-8), which was significantly higher than that by MB alone at 2 (range 1-7) (P<0.05).
conclusionLFIS effectively detects SLNs in breast cancer, projects the fluorescence signals during surgery, and provides a continuous surgical navigation system without the need for a remote monitor. The ICG method navigated by combined LFIS and MB may be a promising alternative tracer for radioisotope in SLN mapping. CLINICAL
trial registrationThis clinical trial was registered with the China Clinical Trial Center, registration number ChiCTR2000039542.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.